Doravirine (Pifeltro®)

Assessment Status Rapid review complete
Drug Doravirine
Brand Pifeltro®
Indication In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
Assessment Process
Rapid review commissioned 06/12/2018
Rapid review completed 16/01/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that doravirine (Pifeltro®) not be considered for reimbursement at the submitted price.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.